At the IGTP TODAY

News

- Campus Can Ruti, Innovation

European Commission’s drive to launch a medical device created in the Hospital and the Germans Trias i Pujol Research Institute to improve the diagnosis and prognosis of the acute ischaemic stroke

The care and treatment provided to people who suffer an ischemic stroke can improve thanks to a technology developed in Catalonia. This is the purpose of Time is Brain (TiB), a start-up that arose from a scientific project carried out by the Hospital and the Germans Trias i Pujol Research Institute (IGTP), which has just received an investment by the European Union of almost 6 million euros in order for the hospitals to count on a pioneering device to manage acute ischaemic stroke.

- Campus Can Ruti

About thirty healthcare and research professionals from institutions belonging to the Can Ruti Campus, among the world’s most renowned scientists

Antoni Bayés, Pere Joan Cardona, Magí Farré, Miquel Àngel Gassull, Manel Puig-Domingo, Manuel Perucho and Jordi Barretina, all past and present members of IGTP staff together with nearly twenty other affiliated researchers and medical staff from Can Ruti Campus institutions -many affiliated to the IGTP- are included in Elsevier's Scopus list, composed of the 200,000 most renowned researchers worldwide.

- Campus Can Ruti

The IGTP hosts the EORTC Pathobiology Group (PBG) Annual Meeting

The European Organisation for Research and Treatment of Cancer (EORTC) Pathobiology Group Annual Meeting took place on October 24 and 25, organized jointly by the Catalan Institute of Oncology (ICO) and the Germans Trias i Pujol Research Institute (IGTP). Over the two-day event, a series of talks on therapies to fight cancer were held both at the IGTP facilities and online.

- Campus Can Ruti

The IGTP presents CARE Translational Program in Cancer Research

CARE, the Translational Program in Cancer Research is the first transversal program promoted by the Germans Trias i Pujol Research Institute (IGTP), and it aims to become a bridge for researchers in the field of cancer who want to bring basic and clinical research together, so that the knowledge and the tools generated in the laboratory can benefit the patient.

The start of a new international clinical trial to improve treatment for tuberculosis with anti-inflammatory agents

The Experimental Tuberculosis Group at the IGTP has set up this trial, coordinated from Can Ruti, within the European project H2020 ‘SMA-TB’. The study will evaluate the efficacy and safety of adding acetylsalicylic acid or ibuprofen to the antibiotic treatments applied for tuberculosis. It is a phase II trial which will be carried out in South Africa and Georgia, two of the countries the WHO has in its sights to control this infectious disease. The trial has been prepared in the midst of the pandemic, with the added challenge of coordinating it with the restrictions and different stages of the epidemic in each of the countries involved.